After a lapse of 3 years, the Ministry of Commerce issued another report on the circulation of medicines: pharmaceutical retail companies led the way in growth!

From the perspective of the overall operating characteristics, the performance of the four major types of companies in the pharmaceutical distribution industry can be said to have their own merits: the concentration of pharmaceutical wholesale companies continues to increase, and sales are showing a rebound trend; the sales of pharmaceutical retail companies have risen steadily, and the growth rate is higher than the overall level of the industry; Pharmaceutical logistics companies have improved their service capabilities and promoted the coordinated development of the supply chain; pharmaceutical e-commerce sales have grown, and integration with offline has entered a new stage of development

Sales of the three major categories declined, and Guangdong continued to rank top in sales

From the perspective of the sales category structure of the entire industry, Western medicine still dominates, with sales accounting for 71.

However, there is little change in the distribution of sales regions.

From the perspective of total regional sales in 2020, Guangdong Province continues to be the champion with a market volume of nearly 256 billion yuan, and Beijing, Shanghai, Jiangsu, Zhejiang, Shandong, Henan, Anhui, Sichuan, and Hubei rank among the top ten lists

The growth rate of retail enterprises is higher than the overall level, and the future must innovate models to meet demand

The sudden new crown pneumonia epidemic in 2020 has brought a lot of impact to the development of various industries in our country.

The growth of pharmaceutical retail companies is obviously due to the fact that they have become an important place for people to purchase medical protection materials and related drugs for epidemic prevention during the epidemic

Standing at the new starting point of the "14th Five-Year Plan", the "Report" predicts that in 2021, as the people pay more and more attention to health, preventive demand will grow, and policies such as Internet + medical insurance payment and national medical insurance negotiation drugs "dual channel" The landing has provided new opportunities for the development of retail pharmacies

Pharmaceutical e-commerce sales accounted for more than doubled, and business expense ratio remained high

Under the catalysis of the new crown epidemic, the "fourth terminal" represented by pharmaceutical e-commerce is rising rapidly, and the operation of pharmaceutical e-commerce has become a major focus of the industry's most attention in this "Report"

Among them, the transaction volume of third-party transaction service platforms was 70.

At present, the difference in sales structure between B2B and B2C is still quite obvious

The industry generally believes that with the launch of the prescription drug online sales policy in the future, the "fourth terminal" is bound to usher in a new stage of development opportunity